Global Compliance: Meets USP, EP, and ICH standards
In vitro and in vivo activity of sEV-semaglutide and sEV-tirzepatide To investigate the in vitro and in vivo activity of sEV-semaglutide or sEV-tirzepatide, we utilized an in vitro cell assay (293 cell line that expresses both the hGLP-1R and CRE firefly luciferase) and an in vivo mouse model (db/db diabetic mice) 36
In a mid-stage clinical trial, the highest weekly injection dose produced about 24% average weight loss at 36 weeks, and the highest oral dose produced about 13% weight loss over 12 weeks
We see the same thing with the association between GLP-1 receptor agonists and macular degeneration, a much more common form of blindness in which people (usually older adults) lose sight at the centre of their vision but can still see around it
The Japanese study mentioned earlier tracked patients who received once-weekly semaglutide after sleeve gastrectomy
338 participants were randomized to semaglutide 2.4 mg weekly, liraglutide 3.0 mg daily, or placebo for 68 weeks
.webp)
